You can buy or sell ALRN and other stocks, options, ETFs, and crypto commission-free!
Aileron Therapeutics, Inc. Common Stock, also called Aileron Therapeutics, is a clinical stage biopharmaceutical company, which focuses on developing and commercializing stapled peptides. Read More Its ALRN-6924 product targets the tumor suppressor p53 for the treatment of a wide variety of cancers. It also offers the MDMX and MDM2. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Markets InsiderMar 12
8 Top Gainers In Healthcare Sector (ALRN, NDRA, DOVA...)
(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Aileron Therapeutics Inc. (ALRN) Aileron is a clinical-stage company developing therapies to treat cancer and other diseases. Gained 51.43% to close Tuesday's (Mar.12) trading at $2.12. News: No news Clinical Trials & Near-term Catalysts: -- A phase IIa expansion of ALRN-6924 as monotherapy in cohorts of patients with relapsed or refractory peripheral T-cell lymphoma is underway. Interim data reported last Decem...
Simply Wall StMar 8
What Type Of Shareholder Owns Aileron Therapeutics, Inc.’s (NASDAQ:ALRN)?
If you want to know who really controls Aileron Therapeutics, Inc. (NASDAQ:ALRN), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented...
Stock Price, News, & Analysis for Aileron Therapeutics
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and ...